SLU-PP-332 & BAM 15

SLU-PP-332 + BAM-15 is a combination capsule that pairs two of the most talked-about metabolic research compounds into a single oral formulation. SLU-PP-332 is a synthetic exercise mimetic that activates estrogen-related receptors (ERRs) to turn on the same fat-burning and endurance gene programs that aerobic exercise triggers in skeletal muscle. BAM-15 is a selective mitochondrial uncoupler that dissipates the proton gradient in mitochondria, forcing cells to burn more calories as heat instead of storing them as fat. Protide Health offers this combination capsule as a research-grade formulation for laboratory and preclinical metabolic studies.

Together, these two compounds target mitochondrial energy metabolism from complementary angles — SLU-PP-332 tells cells to build more mitochondria and burn more fat, while BAM-15 makes existing mitochondria less efficient at storing energy, increasing total caloric expenditure. This dual-mechanism approach has generated significant interest in metabolic disease, obesity, and longevity research.

• Formulation type: Oral combination capsule — two small-molecule metabolic compounds (ERR agonist + mitochondrial uncoupler) in a single convenient dosage form.
• Primary research focus: Energy expenditure, fatty acid oxidation, body composition, mitochondrial function, and metabolic syndrome models.

SLU-PP-332 + BAM-15 Overview & Key Properties

This combination capsule brings together two compounds that have each demonstrated potent metabolic effects in preclinical research, but through fundamentally different mechanisms. No published study has yet tested this exact combination together, but the scientific rationale for pairing them is grounded in their complementary pathways of action on mitochondrial metabolism.

SLU-PP-332 was developed by researchers at Saint Louis University and Washington University School of Medicine. It is a pan-ERR agonist with the strongest activity at ERRα (EC50 ≈ 98 nM), which activates an acute aerobic exercise genetic program in skeletal muscle, increasing oxidative muscle fibers, mitochondrial biogenesis, and fatty acid oxidation (Billon et al., 2023 — ACS Chemical Biology).

BAM-15 (N5,N6-bis(2-Fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a mitochondrial-targeted protonophore that selectively uncouples electron transport from ATP synthesis. It is orally bioavailable and has demonstrated the ability to decrease body fat mass without altering food intake, lean body mass, or body temperature in mouse models (Kenwood et al., 2014; Alexopoulos et al., 2020).

• Formulation type: Oral capsule containing both SLU-PP-332 and BAM-15 for convenient research dosing.
• Suggested storage concept in lab settings: Store in a cool, dry place protected from light and moisture per lab SOPs. Keep capsules in their original sealed container until use.
• Common research models: Diet-induced obese (DIO) mice, ob/ob and db/db mice, C2C12 skeletal muscle cells, metabolic cage studies with indirect calorimetry, and body composition analysis (DEXA or EchoMRI).

SLU-PP-332 + BAM-15 Mechanism of Action

To understand why these two compounds make sense together, think of your cells’ energy system like a factory with two problems: it’s not building enough equipment (mitochondria), and the equipment it has is too efficient at hoarding energy instead of burning it.

SLU-PP-332 solves the first problem. It activates ERRα, a nuclear receptor that acts as a master switch for mitochondrial biogenesis and energy metabolism genes. When ERRα is turned on, cells build more mitochondria, shift from burning sugar to burning fat, and convert muscle fibers into fatigue-resistant oxidative types. SLU-PP-332 triggers this through a specific gene called DDIT4, which activates the same “acute aerobic exercise program” that a workout would (Billon et al., 2023 — ACS Chemical Biology).

BAM-15 solves the second problem. It slips into the inner mitochondrial membrane and allows protons to leak back across without generating ATP. Normally, the energy from food is used to pump protons across this membrane, creating a gradient that drives ATP production. BAM-15 short-circuits this process, forcing the cell to burn more fuel (especially fatty acids) just to maintain its energy supply. The result is increased energy expenditure and heat production without the dangerous side effects seen with older uncouplers like DNP — BAM-15 does not raise body temperature or cause toxicity at effective doses (Alexopoulos et al., 2020).

The combination logic: SLU-PP-332 builds the cellular machinery for fat burning (more mitochondria, more oxidative capacity), while BAM-15 makes that machinery run in overdrive (dissipating stored energy as heat). Together, they target energy metabolism at both the gene expression level and the biophysical level — a dual approach that neither compound achieves alone.

SLU-PP-332 + BAM-15 Research

1. SLU-PP-332: Exercise Mimetic Effects on Muscle and Metabolism

The foundational research on SLU-PP-332 was published in ACS Chemical Biology (2023). When administered to mice, SLU-PP-332 increased type IIa oxidative muscle fibers, boosted mitochondrial function and cellular respiration in skeletal muscle cells, and significantly enhanced treadmill running distance and time. These effects were driven specifically through ERRα activation and the DDIT4 gene pathway (Billon et al., 2023 — ACS Chemical Biology).

A follow-up study published in the Journal of Pharmacology and Experimental Therapeutics (2024) tested SLU-PP-332 in diet-induced obese and ob/ob mice. After 28 days of treatment, treated mice showed decreased fat mass accumulation, increased resting energy expenditure, enhanced fatty acid oxidation, improved glucose tolerance, and reduced liver fat compared to vehicle controls (Billon et al., 2024). These are preclinical animal findings and do not represent approved therapeutic claims.

2. BAM-15: Mitochondrial Uncoupling and Fat Loss Without Appetite Changes

A landmark 2020 study published in Nature Communications demonstrated that BAM-15 reversed diet-induced obesity in mice. Treated animals showed decreased body fat mass, reduced hepatic (liver) fat, decreased inflammatory lipids, and improved insulin sensitivity across multiple tissue types — all without changes in food intake, lean body mass, or body temperature. The compound also showed strong antioxidant effects and no biochemical or hematological markers of toxicity (Alexopoulos et al., 2020).

A separate study in EMBO Molecular Medicine (2020) confirmed that BAM-15 protected against diet-induced obesity through AMPK activation in white adipose tissue. Treatment resulted in dramatic downregulation of lipogenesis genes (fat-building enzymes) and morphological remodeling of adipose tissue. The researchers also showed that BAM-15 improved whole-body glucose disposal and stimulated skeletal muscle fatty acid oxidation, with its glycemic control benefits occurring independently of weight loss itself (Axelrod et al., 2020). These are controlled animal study observations and do not constitute approved treatments.

3. Complementary Pathways: The Rationale for Combination

While no published study has tested SLU-PP-332 and BAM-15 together, the scientific rationale for combining them is built on their non-overlapping mechanisms:

SLU-PP-332 operates at the transcriptional level — it changes which genes are turned on in muscle and metabolic tissues, increasing mitochondrial biogenesis, fatty acid oxidation enzyme expression, and oxidative fiber conversion. Its effects take time to build but produce durable adaptations similar to exercise training (Billon et al., 2023 — ACS Chemical Biology).

BAM-15 operates at the biophysical level — it directly dissipates the proton gradient across the inner mitochondrial membrane, immediately increasing energy expenditure and substrate oxidation. Its effects are more acute and dose-dependent (Alexopoulos et al., 2020).

In theory, SLU-PP-332 would increase the total mitochondrial capacity available in target tissues, while BAM-15 would ensure those mitochondria are running at maximum throughput. Both compounds independently increase fatty acid oxidation and energy expenditure in mouse models, but through entirely different receptor systems (ERR nuclear receptors vs. direct proton gradient disruption). A comprehensive 2023 review in Frontiers in Endocrinology noted BAM-15’s ability to activate AMPK and PGC-1α signaling (Shrestha et al., 2023), pathways that overlap with and may amplify ERR-mediated metabolic programming.

4. BAM-15: Safety Profile Advantages Over Historical Uncouplers

One of the most important aspects of BAM-15 research is its safety profile compared to earlier mitochondrial uncouplers. DNP (2,4-dinitrophenol), the most notorious uncoupler, caused deaths in the 1930s due to its narrow therapeutic window — it raised body temperature dangerously at doses only slightly above the effective range. BAM-15 does not share these risks. In published studies, BAM-15 did not alter body temperature, did not cause toxicity at effective doses, and showed no adverse effects on liver enzymes, blood counts, or organ histology (Alexopoulos et al., 2020; Kenwood et al., 2020).

A 2025 comparative study testing 15 structurally different mitochondrial uncouplers in db/db mice found that BAM-15 had the greatest dose tolerance range in vitro and the best overall effects on body weight, glucose control, and liver steatosis in vivo, outperforming all other tested uncouplers (Alexopoulos et al., 2025). These safety observations are from animal models and cell studies only — no human safety data is available for either compound.

SLU-PP-332 + BAM-15 Dosing Concepts for Lab Research

This section is educational, not prescriptive.

Because this specific combination has not been tested in published research, dosing concepts are extrapolated from the individual compound studies. In SLU-PP-332 research, mice received 50 mg/kg twice daily (IP injection) for metabolic studies. In BAM-15 research, oral doses of 0.1–0.2% mixed into chow (or approximately 50–100 mg/kg via oral gavage) were effective for obesity reversal. The oral capsule formulation offers convenience for research protocols requiring consistent daily administration.

• Focus: Establishing whether the combination produces additive or synergistic effects on energy expenditure, fatty acid oxidation, and body composition endpoints compared to either compound alone.
• Study design: Researchers may consider a 2×2 factorial design (vehicle, SLU-PP-332 alone, BAM-15 alone, combination) with indirect calorimetry, body composition analysis, and tissue-level metabolic assessments.
• Use the peptide dosage calculator to assist with dosing calculations and planning.

SLU-PP-332 + BAM-15 Specifications Table

SLU-PP-332 + BAM-15 FAQs

What is the SLU-PP-332 + BAM-15 combination used for in research?

This combination is designed for research into metabolic energy expenditure, fatty acid oxidation, and body composition. SLU-PP-332 activates exercise-related gene programs through ERR receptors, while BAM-15 directly uncouples mitochondria to increase caloric burn. Together, they target mitochondrial metabolism through two independent and potentially synergistic mechanisms — making them of interest for obesity, metabolic syndrome, and aging research models.

Has this exact combination been studied in published research?

No. As of early 2026, no published study has tested SLU-PP-332 and BAM-15 together. However, both compounds have been individually studied in multiple peer-reviewed publications, and their non-overlapping mechanisms provide a strong theoretical rationale for combination research. This product enables researchers to investigate potential additive or synergistic effects.

Is BAM-15 safe compared to other mitochondrial uncouplers like DNP?

In preclinical animal studies, BAM-15 has demonstrated a significantly better safety profile than historical uncouplers like DNP. Unlike DNP, BAM-15 does not raise body temperature and does not cause toxicity at effective doses. A 2025 comparative study found BAM-15 had the best overall safety and efficacy profile among 15 different uncouplers tested. However, all safety data is from animal models — no human clinical trials have been conducted.

Are SLU-PP-332 and BAM-15 peptides?

Technically, neither SLU-PP-332 nor BAM-15 are peptides — both are small molecules designed through medicinal chemistry. SLU-PP-332 targets nuclear receptors (ERRs) inside cells, while BAM-15 directly interacts with the mitochondrial inner membrane. They are commonly discussed alongside peptides in the research compound space because of overlapping applications in metabolic and longevity research.

Why combine these two compounds instead of using them separately?

The rationale is based on complementary mechanisms. SLU-PP-332 works at the gene expression level — building more mitochondria and upregulating fat-burning enzymes over time, similar to exercise training adaptations. BAM-15 works at the biophysical level — immediately increasing energy expenditure by making existing mitochondria less efficient at ATP production. In theory, combining them creates a “build more engines and run them harder” approach to metabolic research that could exceed the effects of either compound alone.

Where to buy SLU-PP-332 + BAM-15 capsules online?

You can buy SLU-PP-332 + BAM-15 capsules online in the United States at Protide Health. Every compound is backed by science, clearly labeled, and third-party tested for purity and identity.

Conclusion: Summary of SLU-PP-332 + BAM-15 Capsules for Research

The SLU-PP-332 + BAM-15 combination capsule brings together two of the most promising small-molecule metabolic research compounds in a convenient oral formulation. SLU-PP-332 activates the ERR-driven exercise mimetic program — building mitochondrial capacity, shifting fuel use toward fatty acids, and converting muscle fibers to fatigue-resistant types. BAM-15 directly uncouples mitochondrial respiration — burning stored energy as heat, reducing fat accumulation, and improving insulin sensitivity without affecting appetite or lean mass. Their non-overlapping mechanisms make them strong candidates for combination research into metabolic disease, obesity, and energy expenditure.

All research involving SLU-PP-332 + BAM-15 should take place in controlled laboratory and preclinical settings. Neither compound has been tested in human clinical trials, and these preclinical findings do not represent regulatory approval for any therapeutic application. Researchers are encouraged to follow all applicable institutional and regulatory guidelines.

Citations

• Billon C et al., 2023. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology.
• Billon C et al., 2024. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics.
• Alexopoulos SJ et al., 2020. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications.
• Axelrod CL et al., 2020. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine.
• Shrestha R et al., 2023. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Frontiers in Endocrinology.
• Alexopoulos SJ et al., 2025. Diverse actions of 15 structurally unrelated mitochondrial uncouplers in cells and mice. Molecular Metabolism.

Legal Disclaimer for SLU-PP-332 + BAM-15 Capsules

The information provided in this description is for research purposes only. SLU-PP-332 and BAM-15 are not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. This product is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of SLU-PP-332 + BAM-15 in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving these compounds.

Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.